Molecular Psychiatry and Antipsychotics
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 5
Special Issue Editor
Interests: oxytocin; autism; valproate; amygdala; anxiety; rat; elevated plus maze
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Psychiatric diseases place a significant burden on the healthcare system. Schizophrenia is a widespread and devastating psychiatric disorder, affecting approximately one percent of the global population. Antipsychotic drugs primarily exert their effects via D2 dopamine receptors; however, it has been shown that many other neurotransmitter systems are involved in schizophrenia, including serotonergic, cholinergic, noradrenergic, oxytocinergic, and neurotensin systems. While antipsychotics mainly relieve the positive symptoms of schizophrenia, they have also been demonstrated to be effective in treating negative and cognitive symptoms. Nonetheless, the exact molecular mechanisms by which antipsychotics exert their effects are not fully understood. Understanding the underlying mechanisms of schizophrenia symptoms is crucial for the development of more effective therapies.
Dr. László Péczely
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- psychiatric diseases
- schizophrenia
- antipsychotics
- molecular psychiatry
- molecular pathways
- neurotransmitter systems
- positive, negative and cognitive symptoms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
